Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.

@article{mov2010TherapyFM,
  title={Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.},
  author={Jana {\vS}{\'i}mov{\'a} and Marie Indrov{\'a} and Jana Bieblov{\'a} and Romana Miky{\vs}kov{\'a} and Jan Buben{\'i}k and Milan Reini{\vs}},
  journal={International journal of cancer},
  year={2010},
  volume={126 12},
  pages={2997-3004}
}
Natural killer T (NKT) cells are potent modulators of antitumor immunity. Their protective effects can be achieved upon their activation by glycolipid ligands presented in the context of the CD1d molecule. These CD1d-binding glycolipid antigens have been described as potent therapeutic agents against tumors, infections, as well as autoimmune diseases. Immunoregulatory and therapeutic effects of glycolipid ligands depend on their structure and modes of administration. Therefore, more studies are… CONTINUE READING